Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07131514) titled 'HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer' on Aug. 13.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Ruijin Hospital
Condition:
Pancreatic Cancer
Intervention:
Drug: HRS-4642+AG +Adebrelimab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 2025
Target Sample Size: 30
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07131514
Publ...